New blood tests aim to make haemophilia treatment safer for patients with inhibitors

NCT ID NCT02453542

Recruiting now Knowledge-focused Sponsor: Karolinska Institutet Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing new blood tests to see if they can better measure how well bleeding treatments work in people with haemophilia who have developed inhibitors (antibodies that block standard treatment). The researchers will take blood samples from 20 patients before and after they receive bypassing agents (special clotting medicines). The goal is to improve monitoring, making treatment safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bypassing agents (FEIBA or NovoSeven)
What this could lead to: If successful, this could lead to better ways to monitor treatment for haemophilia patients with inhibitors, making therapy safer and more effective.
What could go wrong: This is a small, early-stage study with only 20 participants, so results may not apply to all patients. The new tests may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACQUIRED HEMOPHILIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired hemophilia hemophilia hemophilia A hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA

Contacts and locations

Locations

Karolinska University Hospital
RECRUITING

Solna, Stockholm County, 17176, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.